CD97 promotion of gastric carcinoma lymphatic metastasis is exosome dependent

Daren Liu1 · Chao Li1 · Bogusz Trojanowicz2 · Xiaowen Li1 · Dike Shi1 · Chenni Zhan1 · Zhefang Wang1 · Li Chen1

Received: 3 March 2015 / Accepted: 19 July 2015 / Published online: 2 August 2015 © The Author(s) 2015. This article is published with open access at Springerlink.com

Abstract

Background CD97 knockdown impairs the metastatic capacity of SGC-7901 gastric cancer cells. However, the role of CD97 in the distant lymphatic premetastatic niche formation of gastric cancer remains unknown.

Methods Exosomes and the soluble fraction were isolated from SGC-L (an SGC-7901-cell-derived highly lymphatic metastatic cell line) and CD97-knockdown (SGC-L/CD97-kd) cells, and were co-cultured with gastric cancer cells. The metastatic capacity of the two cell lines was evaluated in vitro and in a footpad lymph node metastasis mouse model. Premetastatic-niche-formation-related proteins were examined immunohistochemically.

Results CD97 expression was ninefold higher in SGC-L cells than in SGC-7901 cells. In vitro, exosomes or conditioned medium from the SGC-L cells enhanced cell proliferation (20 % increase) and invasion (30 % increase) as compared with that from SGC-L/CD97-kd cells (p < 0.01). Intrafootpad injections of SGC-L, but not SGC-L/CD97-kd exosomes or conditioned medium, strongly promoted SGC-L and SGC-L/CD97-kd cell accumulation in the draining lymph nodes (p < 0.01) and increased CD55, CD44v6, α5β1, CD31, epithelial cell adhesion molecule, and CD151 expression. Although the SGC-L/CD97-kd exosomes alone were insufficient for promotion of metastasis, they were partly aided by the SGC-L-cell-derived soluble fraction.

Conclusions The CD97 small isoform promotes SGC-L cell lymphatic metastasis exosome dependently, and aided by the soluble fraction, the exosome-dependent CD97 plays a pivotal role in premetastatic niche formation.

Keyword CD97 · Gastric cancer · Exosomes · Lymphatic metastasis

Introduction

Lymphatic metastasis is the commonest means of gastric carcinoma spread [1]. In metastasis formation, cancer-initiating cells detach from the local tumor and travel to the premetastatic niche in the target organ, organized by long-distance communication [2]. CD97, a member of the epidermal growth factor (EGF)–seven transmembrane subfamily, is overexpressed in most gastric carcinomas, where enhanced CD97 expression in gastric carcinoma is associated with tumor cell dedifferentiation and aggressiveness and directly correlates with clinical pathological parameters such as the tumor–node–metastasis (TNM) classification [3–5]. In most cases, CD97 is only expressed in the primary tumor mass of gastric carcinoma; but in a few cases, especially those with poor differentiation, CD97 expression is enhanced in the regional draining lymph nodes [6]. Elevated CD97 expression and CD44 and CD31 expression were found in the early metastatic regional lymph nodes of an orthotopically implanted gastric cancer mouse model, but their expression was strongly...
downregulated in a CD97/EGF1,2,5 knockdown group [7], which demonstrated that CD97 not only supports local tumor growth, but also promotes lymph node metastasis.

Exosomes are small membrane vesicles secreted by various cell types, including lymphocytes, epithelial cells, stem cells, and tumor cells [8]. Exosomes not only have membrane components but also contain microRNA (miRNA), messenger RNA (mRNA), and other noncoding RNAs, which can be delivered to recipient cells and internalized, where they can be translated and cause host cell silencing [9]. It was reported that tumor-derived exosomes contribute to metastatic niche formation and promote tumor growth in breast cancer [10]. Capitalizing on their long-distance gene-delivering characteristic, exosomes are considered mediators of the intercellular communication between the local tumor and the premetastatic niche in the host organs, which facilitates gastric carcinoma metastasis by promoting premetastatic niche formation.

We used highly lymphatic metastatic (SGC-L) and poorly lymphatic metastatic (SGC-L/CD97-kd, where “kd” represents “knockdown”) gastric cancer cell lines to prove our hypothesis that CD97 promotes gastric carcinoma lymphatic metastasis through exosome-dependent long-distance cross talk. Additionally, to determine whether other tumor-derived components are involved in premetastatic niche formation, we investigated the impact of the soluble fraction on the metastatic potential of the cells.

Materials and methods

Cell lines and animals

The gastric adenocarcinoma cell line SGC-7901 was purchased from ATCC (http://www.atcc.org). The cell line was originally derived from the metastatic lymph node of a patient who had received no prior therapy, and was characterized by pathology and chromosome examination. The cells were propagated in RPMI 1640 medium (Genom Biologic, Hangzhou, China) and 10% fetal bovine serum (FBS), as previously described [7].

The 4–6-week-old female BALB/c nu/nu mice (18–22 g) used in this study were housed in a sterile environment and maintained under a daily 12-h light/dark cycle, which was controlled by qualified staff at the Zhejiang University Laboratory Animal Center, Hangzhou, China. All animal studies were performed in strict accordance with the guidelines for the welfare and use of animals in cancer research of the Committee of the National Cancer Research Institute. The Zhejiang University Animal Research Committee approved the protocol. All surgical procedures were performed with the mice under sodium pentobarbital anesthesia, and all efforts were made to minimize suffering [11].

Establishment of footpad lymph node metastasis mouse model and SGC-L cell generation

Twenty BALB/c nu/nu mice were used for tumor implantation. Subconfluent SGC-7901 cells (1.0 × 10⁶/mL) were injected into the footpad of each mouse. After 6–8 weeks, the mice were killed according to institutional guidelines before they developed signs of distress. The draining popliteal and inguinal lymph nodes were harvested for histological examination and primary cell culture [12]. The lymph nodes were minced into 1-mm³ pieces and digested with collagenase type II in RPMI 1640 medium. The primary culture metastatic tumor cells were propagated and reinjected into the footpads of the mice. After this process had been repeated four times, when the lymph node metastasis rate was more than 70%, the subpopulation offspring of the SGC-7901 cells within the lymph nodes, which had higher lymphatic metastatic ability, was preserved and designated SGC-L.

Cell proliferation assay

Cells (1 × 10³ per well) were cultured in the presence of conditioned medium or exosomes. Proliferation was determined at 24, 48, and 72 h by 3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium (MTS) staining [13]. Cells (1 × 10³ per well) were plated in 200 μL RPMI 1640 medium with tumor-cell-derived conditioned medium or fractions (exosomes, soluble fraction) in 96-well plates. At 24, 48, and 72 h, the growth medium was replaced with 100 μL serum-free medium, and 20 μL MTS solution (Promega, Madison, WI, USA) was added. The absorbance was measured at 490 nm with a microplate reader (Bio-Rad, Hercules, CA, USA).

Invasion and scratch wound assays

Invasion assays were performed with 24-well Transwell™ chambers (Costar, MA, USA) with Matrigel-coated 8-μm filters (BD Biosciences, San Jose, CA, USA). Cells (1.0 × 10⁵) in medium containing 1% FBS were added to the upper chamber; the lower chamber was filled with medium containing 10% FBS as a chemoattractant. After incubation for 24 h, the transmigrated cells were fixed, stained with 0.2% crystal violet (Sigma, Munich, Germany), and counted under a light microscope (Leica, Wetzlar, Germany). The scratch wound assay was done with a standard 200-μL pipette tip in 80% confluent cells. Wound healing was evaluated after 24 h with a light microscope (Leica, Wetzlar, Germany).
CD97 knockdown by miRNA

Four candidate miRNA sequences targeting human CD97 (Table S1) were designed and cloned into pcDNA6.2-GW/ EmGFP-miR vector (Invitrogen, Grand Island, NY, USA). We transfected SGC-L cells with the vectors using Lipofectamine 2000 according to the manufacturer’s protocol (Life Technologies, Grand Island, NY, USA). CD97 silencing was verified by reverse transcription (RT) PCR and Western blotting. The CD97-knockdown cells were designated SGC-L/CD97-kd. Nonsilencing miRNA was used as the control.

Fractionation of conditioned medium

The supernatant of tumor cells cultured in serum-free medium for 24 h was collected and centrifuged (10 min at 300g followed by 20 min at 16,500g) to pelletize the cells and debris. The supernatant was filtered through 0.20-μm filters to remove particles larger than 200 nm and stored as conditioned medium. Briefly, exosomes were pelleted by ultracentrifugation (Beckman Coulter, Fullerton, CA, USA) of the conditioned medium at 120,000g for 70 min at 4 °C; the vesicle-depleted supernatant was termed the soluble fraction, which contains a highly adhesive subfraction [14]. The pelletized exosomes were washed in phosphate-buffered saline (PBS) and pelleted by ultracentrifugation at 120,000g for 70 min. The exosome pellets were resuspended in PBS and stored at −80 °C until use. The total protein concentration of the exosomes was measured with an enhanced bicinchoninic acid protein assay kit (Beyotime, Nantong, China).

Electron microscopy

Exosomes were resuspended in 1 % glutaraldehyde in PBS (pH 7.4) and pipetted onto Formvar carbon-coated electron microscopy grids. The sample was stained with 2 % phosphotungstic acid for 1 min and dried under an electric incandescent lamp for 10 min before it was viewed under a Tecnai 10 transmission electron microscope (Philips, Amsterdam, Netherlands). Exosome size was measured with use of the scale bar.

Total RNA extraction and RT-PCR

Total RNA was extracted with TRIzol (Life Technologies). RT-PCR was performed according to the manufacturer’s protocol. Table S2 lists the primers used.

Western blotting

Total proteins were resolved and transferred to poly (vinylidene difluoride) membranes (Millipore, Darmstadt, Germany). After they had been blocked with 5 % nonfat milk, the membranes were incubated (overnight, 4 °C) with anti-CD97 (1:5000, Abnova, Taipei, Taiwan), anti-CD55 (1:5000, Abcam, Cambridge, MA, USA), anti-CD44v6 (1:1000, Abcam), anti-EGF receptor (EGFR; 1:10000, Abcam), anti-human EGFR2 (HER2; 1:200, Abcam), anti-heat shock protein 70 (1:1000, Abcam), anti-CD9 (1:1000, Abcam), and anti-β-actin (1:5000, Bio-Ker, Gessate, Italy) antibodies. Then, the membranes were incubated with horseradish peroxidase conjugated goat anti-mouse immunoglobulin G or goat anti-rabbit immunoglobulin G (1:5000; Bio-Ker) and developed with an enhanced chemiluminescence kit (Millipore, Darmstadt, Germany).

Immunohistochemistry

Formalin-fixed, paraffin-embedded sections (4 μm) were subjected to pretreatment by heat-mediated antigen retrieval with sodium citrate buffer (pH 6) and incubated overnight at 4 °C with anti-CD97 (1:200; Abnova), anti-CD44v6 (1:200; Abcam), anti-CD31 (1:200; Abcam), anti-α5β1 (1:200; Abnova), anti-CD31 (1:400; Abnova), anti-epithelial cell adhesion molecule (EpCam; 1:400; Abnova), and anti-CD151 (1:400; Abnova) antibodies. The sections were incubated with horseradish peroxidase conjugated secondary antibody (1:2000) and counterstained with Mayer’s hematoxylin (Invitrogen, Grand Island, NY, USA).

Statistical analysis

Statistical analysis was performed by Student’s t test and one-way analysis of variance. Bonferroni correction was applied for multiple comparisons, dividing the significance level by the number of tested variables. All experiments were performed at least in triplicate; the results are expressed as the mean ± standard deviation. A probability (p) of 0.05 or less was considered statistically significant.

Results

Cancer stem cell marker expression was higher in lymph nodes of gastric adenocarcinoma with lower degrees of differentiation

Gastric adenocarcinoma tissue samples at the invasive front of the tumor mass and perigastric lymph nodes (along the greater gastric curvature) were harvested for evaluation. All regional lymph nodes were microscopically confirmed as nonmetastatic. Immunohistochemical investigation revealed that CD44v6 and CD97 expression was high in all...
tumor tissues independently of their degree of differentiation. There was higher CD44v6 and CD97 expression in the regional lymph nodes from poorly differentiated gastric cancer tissues with higher metastatic potential than in lymph nodes from well-differentiated gastric cancer (Fig. 1a). These findings suggest that, in addition to its association with tumor differentiation and invasion, CD97 may participate in premetastatic niche formation.

**Footpad lymph node metastasis mouse model and SGC-L cell generation**

Human SGC-7901 cells were cultured, harvested, and injected into the footpads of BALB/c nu/nu mice. On days 7, 14, and 28 after injection, the mice were killed, and the footpad draining lymph nodes (popliteal and inguinal) were collected (Fig. 1b, c). Apart from the gradually increasing

![Image of CD44v6 and CD97 expression in cancer tissues and regional lymph nodes](image)

**Fig. 1** a Cancer tissues and regional lymph nodes of well-differentiated and poorly differentiated gastric adenocarcinoma showing high CD44v6 and CD97 expression ($\times$200). Staining in the regional lymph nodes of poorly differentiated gastric cancer was stronger than for well-differentiated tumor samples ($\times$200). b Local tumor growth 0, 7, 14, and 28 days after SGC-7901 cell injection. c Enlarged popliteal lymph node (white arrow) and inguinal lymph node (black arrow) on day 28. d Hematoxylin and eosin stained popliteal lymph node showing metastatic tumor cells on day 28 after SGC-7901 cell injection ($\times$400). D day
tumor volume in situ, enlarged popliteal and inguinal lymph nodes were detected on day 28. Hematoxylin–eosin staining revealed metastatic tumor cells in the popliteal lymph nodes (Fig. 1d), confirming the footpad lymph node metastasis mouse model. To generate a subpopulation of gastric cancer cells with higher metastatic ability, lymph nodes with metastatic tumor cells were filtered through fine gauze, cultured, and the harvested metastatic tumor cells were reinjected into the footpads of the mice. After 28 days, the metastatic tumor cells were harvested from the draining lymph nodes. The separation procedure was repeated four times, and we obtained the SGC-L subpopulation.

**Proliferative, migratory, and invasive abilities were stronger in SGC-L cells**

The MTS assay revealed that SGC-L cell proliferation rates were 60 % higher than those of SGC-7901 cells (Fig. 2a). In the scratch wound assay, continuous movement was observed in both groups, but the SGC-L-cell-free scratch region was smaller (42 %) than that of SGC-7901 cells, indicating the enhanced motility of the SGC-L cells (Fig. 2b, d). The migration assay demonstrated more migrated SGC-L cells than SGC-7901 cells, confirming the scratch wound assay results (data not shown). The invasion assay revealed two times more transmigrated SGC-L cells than SGC-7901 cells, demonstrating the increased invasive ability of SGC-L cells (Fig. 2c, e). These observations demonstrate the enhanced tumor-promoting potential of SGC-L cells as compared with SGC-7901 cells.

**Tumor-related cell membrane receptor expression was enhanced in SGC-L cells**

Enhanced CD97 expression in gastric cancer is associated with more evident malignancy [4]. Here, the proliferative, migratory, and invasive abilities and CD97 expression markedly differed in the SGC-7901 and SGC-L cells. To...
verify our hypothesis, we evaluated CD97 expression in SGC-7901 and SGC-L cells by RT-PCR and Western blotting. SGC-L cells expressed more CD97 transcripts (membrane receptors): CD55 (a CD97 ligand), CD44v6 (a cancer stem cell marker), and two potential tumor therapeutic markers, EGFR and HER2. There was higher mRNA (Fig. 3c) expression of CD55 (2.9-fold), CD44v6 (2.2-fold), and EGFR (1.6-fold) in SGC-L cells than in SGC-7901 cells, as well as higher protein expression (Fig. 3d). The enhanced membrane receptor expression suggested that, in addition to the tumor-promoting role of CD97, other related membrane receptors or an enriched membrane receptor domain may enhance SGC-L cell invasive ability. Nonmetastatic inguinal lymph nodes harvested on day 28 after injection for immunohistochemical evaluation (Fig. 3e) revealed gradually concentrated CD97, CD55, CD44v6, α5β1, CD31, and epithelial cell adhesion molecule (EpCam) expression on days 7, 14, and 28 after tumor cell injection (×200). Three asterisks p < 0.001, ns not significant.
Fig. 4 Transfectants with stable CD97 knockdown. a Reverse transcription PCR analysis was performed on SGC-L cells, nonsilencing microRNA clones (SGC-L/ns), and SGC-L/CD97-knockdown (SGC-L/CD97-kd) clones; reference, β-actin. b Western blot detection of the approximately 80-kDa CD97 protein in total SGC-L, SGC-L/ns, and SGC-L/CD97-kd cell extracts. c CD97 knockdown dramatically decreased relative CD55 and CD44v6 messenger RNA (mRNA) expression in SGC-L/CD97-kd cells as compared with SGC-L or SGC-L/ns cells. Epidermal growth factor receptor (EGFR) and human EGFR2 (HER2) levels were not significantly affected. d Decreased CD55 and CD44v6 protein expression in SGC-L/CD97-kd cells as compared with the corresponding controls. e 3-(4,5-Dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium (MTS) assay revealing significantly decreased proliferation rates in SGC-L/CD97-kd clones at 48 and 72 h as compared with the corresponding controls. f Scratch wound assay and g, h Matrigel invasion assay showing significantly decreased motility and invasive ability, respectively, of SGC-L/CD97-kd clones as compared with SGC-L or SGC-L/ns controls (×200). Two asterisks p < 0.01, three asterisks p < 0.001, ns not significant
Generation of transfectants with stable knockdown of CD97 small isoform and identification of tumor-derived exosomes

To investigate the role of CD97 in premetastatic niche formation and its possible mechanism, we generated CD97 small isoform (CD97iso) knockdown clones of SGC-L cells and isolated the tumor-derived exosomes. The CD97iso silencing efficiency was verified by RT-PCR and Western blotting. There was significant CD97iso knockdown and a parallel decrease of the levels of other CD97 isoforms (transcript and protein level) in the SGC-L/CD97-kd group as compared with the control (Fig. 4a, b). CD97 silencing led to significantly decreased levels of CD55 and CD44v6 as compared with the corresponding controls. However, CD97 knockdown did not affect EGFR and HER2 expression (Fig. 4c, d).

We used proliferation, migration, and invasion assays to investigate whether CD97 knockdown affected the behavior of the cells with high metastatic potential. The proliferative (Fig. 4e), migratory (Fig. 4f), and invasive (Fig. 4g, h) abilities of the SGC-L/CD97-kd clone were significantly decreased as compared with those of the control group.

On the basis of their unique size and density, the exosomes released by the SGC-L and SGC-L/CD97-kd cells were isolated and observed under an electron microscope. The exosomes appeared as small, closed, 30–100-nm-wide vesicles bound by a lipid bilayer, which was consistent with the reported size of exosomes [8]. We also detected the exosomal markers heat shock protein 70 and CD9 in the membrane vesicles (Fig. 5), which confirmed our successful isolation of tumor-derived exosomes [15, 16].

SGC-L-cell-derived exosome and soluble fraction involvement and promotion of tumor cell proliferation and invasion in vitro

To support the hypothesis that exosomes, and the soluble fraction, promote long-distance metastasis and premetastatic niche formation, we separated exosomes and the soluble fraction from the conditioned medium by ultracentrifugation.

SGC-L cells were co-cultured with SGC-L-derived or SGC-L/CD97-kd-derived conditioned medium, exosomes, or the soluble fraction in vitro (Fig. 6). As expected, the SGC-L-derived conditioned medium dramatically enhanced cell proliferation (20 % increase) and invasion (30 % increase) as compared with the control medium. Such effects were observed, although less pronounced, when SGC-L/CD97-kd cells were incubated with SGC-L-derived conditioned medium. SGC-L/CD97-kd-derived conditioned medium impaired cell proliferation and did not influence SGC-L cell invasion. The findings confirm that SGC-L-derived conditioned medium promotes cell invasion and is involved in distant tumor metastasis.

To examine which conditioned medium components accounted for the metastasis-promoting effects, we isolated and investigated exosomes and the soluble fraction from SGC-L and SGC-L/CD97-kd cells. Similarly to the conditioned medium, SGC-L exosomes significantly promoted SGC-L (25 % increase) and SGC-L/CD97-kd (15 % increase) cell proliferation, albeit with less efficacy than that of conditioned medium. SGC-L/CD97-kd exosomes and soluble fraction did not affect cell invasive ability. However, co-culture of the cells with the SGC-L cell component
fractions (i.e., SGC-L exosomes plus SGC-L/CD97-kd soluble fraction, or SGC-L soluble fraction plus SGC-L/CD97-kd exosomes) also enhanced cell proliferation and invasion. It appears that accelerated proliferation and enhanced invasion require both the soluble fraction and exosomes, and exosomes are mainly responsible for these effects. We investigated the effects of exosomes at 0, 50, 100, 200, and 400 µg/mL on cellular proliferation with the MTS assay. SGC-L exosomes increased SGC-L and SGC-L/CD97-kd cell proliferation dose dependently (data not shown).

SGC-L-cell-derived conditioned medium and exosomes promoted SGC-L/CD97-kd cell lymphatic metastasis and modulated protein expression within premetastatic nodes

To evaluate the role of SGC-L or SGC-L/CD97-kd exosomes in lymph node metastasis, we established a footpad lymph node metastatic model. SGC-L or SGC-L/CD97-kd conditioned medium or exosomes were injected into the footpads of BALB/c nu/nu mice for five consecutive days and twice weekly after tumor cell implantation. On days 7, 14, 21, 28, and 35 days after implantation, we collected the popliteal and inguinal lymph nodes and counted the metastatic tumor cells stained with C4.4A. SGC-L exosomes increased SGC-L and SGC-L/CD97-kd cell proliferation dose dependently (data not shown).

Discussion

We used a mouse footpad lymph node metastasis model and the highly lymphatic metastatic SGC-L cell line to demonstrate that CD97iso promotes gastric cancer cell metastasis exosome dependently. Furthermore, we demonstrated that CD97, assisted by the soluble fraction, plays a pivotal role in premetastatic niche formation.

Metastatic niche formation in the premetastatic organ plays an essential role in tumor metastasis [1]. Although many molecules, including CD44v6 [17], c-Met [18], urokinase-type plasminogen activator receptor [19], CD97 [7], CD9 [20], CD151 [21], CD11b [14], D6.1A [20], CD13 [22], CD49 [23], CD104 [24], EpCam [25], and claudin 7 [26], participate in this process, the recruitment of these molecules to the metastatic site and the mechanism of long-distance communication with the local tumor remain unknown. Exosomes deliver proteins, mRNA, and miRNA to recipient targets distant from the local tumor, and are excellent messenger candidates for long-distance signal transduction [27]. We found that exosomes from gastric cancer cells lacking CD97iso were less effective promoters of lymphatic metastasis and that local tumor development was clearly impaired. Consequently, it appears that exosomes are the key metastatic factor in gastric carcinoma, and their participation in metastasis and niche formation depends on CD97iso expression.

CD97 is a member of the EGF–seven transmembrane subfamily that belongs to class B G-protein-coupled receptors, and is produced as three isoforms containing three (EGF1,2,5), four (EGF1–3,5), or five (EGF1–5) EGF domains [3, 28]. There are three CD97 ligands: chondroitin sulfate, a glycosaminoglycan that binds specifically to the CD97 large isoform (CD97/EGF1–5) and affects cell attachment [29]; α5β1 integrin, which binds via the Arg-Gly-Asp motif in the stalk region of CD97 [30]; and CD55, a glycosylphosphatidylinositol-linked membrane protein that binds specifically to CD97iso [31]. Differing from chimpanzees, most CD97 transcripts in humans encode the smallest isoform [32], suggesting that total CD97 mainly presents CD97iso characteristics. Consequently, CD97iso is a suitable subject for investigation.

CD55, or decay-accelerating factor, plays a crucial role in protecting the cell membrane from complement-mediated attack and lysis [33]. Early-stage gastric carcinomas are easily exposed to the complement attack environment, and tumor cells expressing CD55 protein can escape complement lysis [34]. Herein, CD97iso knockdown decreased CD55 expression, suggesting that CD97-mediated CD55 knockdown disrupts the membrane attack complex and exposes carcinoma cells to complement attack. The enhanced CD97 expression promoted local tumor progression, supporting our findings.

CD97 knockdown also decreased the levels of CD44, which is expressed in several leukemia and carcinoma cell types and is a marker of cancer-initiating cells [35]. CD44v6 overexpression promotes metastasis formation by its associating with and altering cytoskeletal proteins, integrins, and tetraspanin-enriched microdomains [36]. Here, the CD97-mediated CD44v6 expression decrease affected tumor cell biological behavior and reduced tumor cell metastatic ability. These findings demonstrate the
Fig. 7 The impact of tumor cell conditioned medium/exosomes on metastasis. a Immunohistochemical investigation of CD97, CD55, CD44v6, αβ1, CD31, epithelial cell adhesion molecule (EpCam), and CD151 expression in inguinal lymph nodes on day 35 (×200). b C4.4A staining and fluorescence-activated cell sorting of metastatic tumor cells within inguinal lymph nodes (LN) on days 7, 14, 21, 28, and 35.
possible involvement of CD44-dependent signal pathway cross talk with CD97 in premetastatic niche formation.

Increasing evidence shows that tumor-derived exosomes promote tumor progression through various mechanisms [10, 37]. Koga et al. [38] reported that exosomes secreted by BT-474 human breast adenocarcinoma cells attach to cell surfaces and increase the proliferation of the secreting cells. In gastric carcinoma, tumor-derived exosomes promote tumor cell proliferation via phosphatidylinositol 3-kinase/Akt activation [39]. However, it has been speculated that not only exosomes participate in long-distance premetastatic niche formation. To prove this hypothesis, we established a footpad lymph node metastasis mouse model. Conditioned medium from the highly metastatic cells established in this model promoted cell proliferation and invasion independently of CD97 expression. In contrast, conditioned medium from SGC-L/CD97-kd cells exerted weak tumorigenic effects. These data demonstrate that CD97 iso knockdown affects not only cell biological behavior, but also remotely influences target cells through microvesicle-mediated signal transduction.

We demonstrated the essential role of exosomes in promoting gastric carcinoma cell invasion and metastasis. In our studies, the exosomes obtained acted as autonomous units that increased cell metastatic ability and the transfer of cells to the draining lymph nodes. The soluble fraction, which contains so-called adhesive markers, did not induce cell metastatic ability sufficiently. Although the SGC-L/CD97-kd exosomes maintained a structure similar to that of the SGC-L exosomes, they could not induce the premetastatic effects. The mechanisms responsible for these actions are largely unknown, but the involvement and alteration of membrane protein expression are considerable. In addition to the increased CD97, CD55, and CD44v6 expression within the draining inguinal lymph nodes pretreated with SGC-L conditioned medium or exosomes, α5β1, CD31, CD151, and EpCam levels were subsequently elevated. Most of these proteins are involved in active tumor cell migration and are related to poor prognosis in breast cancer, pancreatic cancer, colorectal cancer, and non-small-cell lung cancer [21, 22, 25, 40].

Several features of pancreatic-cancer-initiating cells are mostly preserved in weakly metastatic ASML CD44v6-knockdown cells; the tetraspanins are unimpaired in ASML CD44v6-knockdown exosomes, which might contribute to their metastasis-supporting activity [17]. However, we found that tetraspanins, e.g., α5β1, were significantly downregulated in the premetastatic niche of the SGC-L/CD97-kd exosome group, which not only had no supporting effect but also displayed increased resistance to tumor cell invasion in vitro. These findings suggest that altered CD44 expression may partly alter tetraspanin expression. Tetraspanin expression alteration within the tetraspanin-enriched microdomain during premetastatic niche formation is not always CD44 related; it is also potentially related to CD97, and may be involved in CD97-induced granulocytosis [41]. However, the mechanism requires clarification. Moreover, there was statistically significantly greater vessel density (CD31) in the premetastatic lymph nodes, which was potentially due to the angiogenesis-stimulating effect of CD97/EGF1–5.

In summary, we used the footpad lymph node metastasis mouse model and conditioned medium fractionation to demonstrate that CD97 promotes gastric carcinoma cell proliferation, migration, and invasion in vitro and contributes to premetastatic niche formation via exosomes. Although exemplified in an animal model, the findings require validation to demonstrate their relevance in human cancer progression.

Acknowledgments We are grateful to Yongfa Zhu for his excellent technical assistance with pathology. This study was supported by the National Natural Science Foundation of China (no. 81101837), Zhejiang Medical Health Science and Technology Plan (no. 2013KYB124), and Zhejiang Provincial Natural Science Foundation (no. LY15E010005). The funders had no role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Compliance with ethical standards

All institutional and national guidelines for the care and use of laboratory animals were followed.

Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.

References

1. Regenbrecht CR, Lehrah H, Adjaye J. Stemming cancer: functional genomics of cancer stem cells in solid tumors. Stem Cell Rev. 2008;4:319–28.
2. Bissell MJ, Labarge MA. Context, tissue plasticity, and cancer: are stem tumor cells also regulated by the microenvironment? Cancer Cell. 2005;7:17–23.
3. Aust G, Steinert M, Schutz A, Boltze C, Wahlbuhl M, Hamann J, et al. CD97, but not its closely related EGF-TM7 family member EMR2, is expressed on gastric, pancreatic, and esophageal carcinomas. Am J Clin Pathol. 2002;118:699–707.
4. Liu Y, Chen L, Peng SY, Chen ZX, Hoang-Vu C. Role of CD97stall and CD55 as molecular markers for prognosis and therapy of gastric carcinoma patients. J Zhejiang Univ Sci B. 2005;6:913–8.
5. Liu Y, Chen L, Peng S, Chen Z, Gimm O, Finke R, et al. The expression of CD97/EGF and its ligand CD55 on marginal epithelium is related to higher stage and depth of tumor invasion of gastric carcinomas. Oncol Rep. 2005;14:1413–20.
6. Liu D, Trojanowicz B, Radestock Y, Fu T, Hammke J, Chen L, et al. Role of CD97 isoforms in gastric carcinoma. Int J Oncol. 2010;36:1401–8.
7. Liu D, Trojanowicz B, Ye L, Li C, Zhang L, Li X, et al. The invasion and metastasis promotion role of CD97 small isoform in gastric carcinoma. PLoS One. 2012;7:e39989.
8. Vlassov AV, Magdaleno S, Setterquist R, Conrad R. Exosomes: current knowledge of their composition, biological functions, and diagnostic and therapeutic potentials. Biochim Biophys Acta. 2012;1820:940–8.
9. Simons M, Raposo G. Exosomes–vesicular carriers for intercellular communication. Curr Opin Cell Biol. 2009;21:575–81.
10. Suetsugu A, Honna K, Saji S, Moriwaki H, Ochiya T, Hoffman RM. Imaging exosome transfer from breast cancer cells to stroma at metastatic sites in orthotopic nude-mouse models. Adv Drug Deliv Rev. 2013;65:383–90.
11. Workman P, Aboagye EO, Balkwill F, Balmain A, Bruder G, Chaplin DJ, et al. Guidelines for the welfare and use of animals in cancer research. Br J Cancer. 2010;102:1555–77.
12. Uyama R, Hong SH, Nakagawa T, Yazawa M, Kadosawa T, Mochizuki M, et al. Establishment and characterization of eight feline mammary adenocarcinoma cell lines. J Vet Med Sci. 2005;67:1273–6.
13. Gauduchon J, Gouilleux F, Maillard S, Marsaud V, Renoir JM, Zoëler M. Tetraspanins: push and pull in suppressing and promoting metastasis. Nat Rev Cancer. 2009;9:40–55.
14. Ballas ZK, Buchta CM, Rosean TR, Heusel JW, Shey MR, et al. Role of CD97 isoforms in gastric carcinoma. Int J Oncol. 2014;40:1427–35.
15. Lee KH, Choi EY, Hyun MS, Jang BI, Kim TN, Lee HJ, et al. Functions and therapeutic roles of exosomes in cancer. Front Oncol. 2014;4:127.
16. Cho JA, Lee BS, Park JS, Yon SJ, Sung SN, Cho SY, et al. The expression and action of decay-accelerating factor (CD55) in human malignancies and cancer therapy. Cell Oncol. 2006;28:223–32.
17. Yue S, Mu W, Zöller M. EpCAM-associated claudin-7 supports lymphatic spread and drug resistance in rat pancreatic cancer. Int J Cancer. 2013;133:855–66.
18. Galle J, Sittig D, Hanisch I, Wobus M, Wandel E, Loeffler M, et al. Individual cell-based models of tumor-environment interactions: multiple effects of CD97 on tumor invasion. Am J Pathol. 2006;169:1802–11.
19. Kwakkenbos MJ, Kop EN, Stacey M, Matmata M, Gordon S, Lin HH, et al. The EGF-TM7 family: a postgenomic view. Immunogenetics. 2004;55:655–66.
20. Wang T, Ward Y, Tian L, Lake R, Guedez L, Stetler-Stevenson WG, et al. CD97, an adhesion receptor on inflammatory cells, stimulates angiogenesis through binding integrin counterreceptors on endothelial cells. Blood. 2005;105:2836–44.
21. Qu YM, Haino M, Kelly K, Song WC. Structural characterization of mouse CD97 and study of its specific interaction with murine decay-accelerating factor (DAF, CD55). Immunology. 1999:98:303–11.
22. Eichler W. CD97 isoform expression in leukocytes. J Leukoc Biol. 2000;68:561–7.
23. Mikesch JH, Schier K, Roeter G, Simon R, Buerger H, Brandt B. The expression and action of decay-accelerating factor (CD55) in human malignancies and cancer therapy. Cell Oncol. 2006;28:223–32.
24. Nowicki S, Nowicki B, Pham T, Hasan R, Nagamani M. Expression of decay accelerating factor in endometrial adenocarcinoma is inversely related to the stage of tumor. Am J Reprod Immunol. 2001;46:144–8.
25. Marhaba R, Klingbeil P, Nübel T, Nazarenko I, Bächler MW, Zöller M. CD44 and EpCAM: cancer-initiating cell markers. Curr Mol Med. 2008;8:784–804.
26. Comoglio PM, Giordano S, Trusolino L. Drug development of MET inhibitors: targeting oncogene addiction and expedience. Nat Rev Drug Discov. 2008;7:504–16.
27. Günthert U, Hofmann M, Rudy W, Reber S, Zöller M, Haussmann I. A new variant of glycoprotein CD44 confers metastatic potential to rat carcinoma cells. Cell. 1991;65:13–24.
28. Qu JG, XU XJ, ZHAO MF, TENG YE, ZHANG Y, HOU KZ, et al. Gastric cancer exosomes promote tumour cell proliferation through PI3 K/Akt and MAPK/ERK activation. Dig Liver Dis. 2009;41:875–80.